MicroRNA master regulator of hematopoiesis may also hold the key to B-cell lymphoma pathogenesis and therapy.

Lawrie, CH.

Translational Cancer Research. 2016; 5: 913-915. FI: 1,167 (Q4).

Sensitivity Limit of Nanoparticle Biosensors in the Discrimination of Single Nucleotide Polymorphism.

Sanroman-Iglesias M, Lawrie CH, Schafer T, Grzelczak M, Liz-Marzan LM.

Acs Sensors. 2016; 1: 1110-1116. FI: 0 (Q4).

Catalysis by multifunctional polyelectrolyte capsules.

Hussain S, Zajif Z, Mikhail VH, Irshad P, Wolfgang J, Carregal-Romero S.

Rsc Advances. 2016; 6: 81569-81577. FI: 3,108 (Q2).

Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.

Lopez-Lopez E, Gutierrez-Camino A, Astigarraga I, Navajas A, Echebarria-Barona A, Garcia-Miguel P, Garcia de Andoin N, Lobo C, Guerra-Merino I, Martin-Guerrero I, Garcia-Orad A.

Pharmacogenomics. 2016; 17: 731-741. FI: 2,35 (Q3).

Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile.

Gonzalez-Martin A, Alba E, Ciruelos E, Cortes J, Llombart A, Lluch A, Andres R, Alvarez I, Aramenda JM, Ayala de la Pena F, Barnadas A, Batista N, Calvo L, Galve E, Garcia-Palomo A, Garcia-Saenz, JA, de la Haba J, Lopez R, Lopez-Vivanco G, Martinez-Janez N, Martinez de Duenas E, Plazaola A, Rodriguez-Lescure A, Ruiz M, Sanchez-Rovira P, Santaballa A,Segui MA, Tusquets I, Zamora P, Martin M.

Current Cancer Drug Targets. 2016; 16: 415-428. FI: 2,992 (Q3).

Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial.

Martínez E, Martínez M, Rico M, Hernández B, Casas F, Viñolas N, Pérez-Casas A, Dómine M, Mínguez J.

Oncotargets And Therapy. 2016; 9: 1057-1066. FI: 1,653 (Q3).

Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.

Peñalver FJ, Delgado J, Loscertales J, Sastre JL, Peña A, Olave MT, Osorio S, de la Fuente A, Salar A, Grande C, Pérez Ceballos E, Debén G, Echeveste A, Casado F, de la Rubia J, Lahuerta JJ, Mateos MV.

European Journal Of Haematology. 2016; 96: 532-540. FI: 2,653 (Q2).

Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy.

Pérez R, Durán MS, Mayans J, Soler A, Castillo I, Jurado M, Ribas P, Menchaca Echevarria MC, Hernandez MT, Lopez MD, Echeveste A, Bailen Garcia A, Lopez S, Baquero J, Ramirez G.

European Journal Of Haematology. 2016; 96: 417-424. FI: 2,653 (Q2).

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.

Lainez N, García-Donas J, Esteban E, Puente J, Sáez MI, Gallardo E, Pinto-Marín Á, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Duran MA, Lázaro-Quintela M, González Del Alba A, Méndez-Vidal MJ, Chirivella I, Afonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnáiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Fernández Parra E, Villa Guzmán JC, Martínez-Ortega E, Belén González M, Morán M, Suarez-Paniagua B, Lecumberri MJ, Castellano D.

Bmc Cancer. 2016; 16: 135-135. FI: 3,288 (Q2).

Why some tumours trigger neovascularisation and others don’t: the story thus far.

Adighibe O, Leek RD, Fernandez-Mercado M, Hu J, Snell C, Gatter KC, Harris AL, Pezzella F.

Chinese Journal Of Cancer. 2016; 35: 18-18. FI: 4,111 (Q2).

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.

Martin M, Brase JC, Ruiz A, Prat A, Kronenwett R, Calvo L, Petry C, Bernard PS, Ruiz-Borrego M, Weber KE, Rodriguez CA, Alvarez IM, Segui MA, Perou CM, Casas M, Carrasco E, Caballero R, Rodriguez-Lescure A.

Breast Cancer Research And Treatment. 2016; 156: 81-89. FI: 3,626 (Q2).

Blu-ray based optomagnetic aptasensor for detection of small molecules.

Yang J, Donolato M, Pinto A, Bosco FG, Hwu ET, Chen CH, Alstrøm TS, Lee GH, Schäfer T, Vavassori P, Boisen A, Lin Q, Hansen MF.

Biosensors & Bioelectronics. 2016; 75: 396-403. FI: 7,78 (Q1).

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression.

Pellagatti A, Roy S, Di Genua C, Burns A, McGraw K, Valletta S, Larrayoz MJ, Fernandez-Mercado M, Mason J, Killick S, Mecucci C, Calasanz MJ, List A, Schuh A, Boultwood J.

Leukemia. 2016; 30: 247-250. FI: 11,702 (Q1).

Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.

Mateos MV, Oriol A, Martínez-López J, Teruel AI, Bengoechea E, Palomera L, de Arriba F, Esseltine DL, Cakana A, Pei L, van de Velde H, Miguel JS.

Annals Of Hematology. 2016; 95: 2033-2041. FI: 3,083 (Q2).